Chardan Capital Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)
I'm PortAI, I can summarize articles.
Chardan Capital has maintained a Buy rating on 4D Molecular Therapeutics (FDMT) with a price target of $26.00, according to analyst Geulah Livshits. Livshits, a 5-star analyst, has an average return of 22.2% and a 41.55% success rate. Other analysts, including Evercore ISI's Jonathan Miller, also rated FDMT as a Buy, while Morgan Stanley upgraded it to a Hold on November 6.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments